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A simple and high throughput method was developed and validated for simultaneous determination of
valproic acid and its two toxicant ene-metabolites, 2-enevalproic acid and 4-enevalproic acid in epilepsy
patient plasma using liquid chromatography–tandem mass spectrometry. Probenecid was used as in-
ternal standard and solid-phase extraction was selected for sample preparation. A chromatographic
separation was performed on an Agilent Poroshell SB-C18 column (50 mm4.6 mm i.d., 2.7 μm) by an
optimized gradient elution at a ﬂow rate of 0.9 mL/min. The total run time was 7 min. Electrospray
ionization was used in negative ion mode by multiple reaction monitoring of the precursor-to-product
ion transitions at m/z 143.0-143.0 for valproic acid, m/z 140.9-140.9 for 2-enevalproic acid and
4-enevalproic acid for their poor fragments, and m/z 283.9-239.9 for probenecid. The results showed
good linearity of valproic acid, 2-enevalproic acid and 4-enevalproic acid in their respective linear ranges.
The correlation coefﬁcients were more than 0.998. The intra- and inter-day precision of the assay was
less than 11.0% and the accuracy ranged from 2% to 12%. This analytical method was successfully applied
to assay plasma concentrations of valproic acid and its two ene-metabolites in epilepsy patient plasma
and used for therapeutic drug monitoring.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Valproic acid (VPA, Fig. 1A) is one of the most widely used
antiepileptic drugs, which has broad-spectrum antiepileptic ac-
tivity.VPA possesses the best therapeutical effect on petit mal and
shows individual difference among epilepsy patients [1]. It is no-
table that the administration of VPA may be closely associated
with rare but serious hepatotoxicity with or without hepatone-
crosis [2]. Metabolism is an uppermost route of VPA elimination,
only with 1%–3% of an orally administered dose excreted un-
changed by urine. The bioconversion of VPA relates to three im-
portant metabolic pathways: (ⅰ) approximately 50% of VPA is
mediated by UDP-glucuronosyltransferases (UGTs); (ⅱ) 40% of VPA
experiences mitochondrial β-oxidation; (ⅲ) almost 10% of VPA ison and hosting by Elsevier B.V. Th
University.
g Metabolism, College of Life
0012, China.metabolized by CYP3A4, CYP2C19 and CYP2C9 (cytochrome P-450)
into oxidative metabolites. Glucuronidation and β–oxidation are
the most important metabolic pathways of VPA [3]. 2-enevalproic
acid (2-ene VPA) is provided by mitochondrial beta-oxidation of
VPA and the formation of 4-enevalproic acid (4-ene VPA) is
mediated by CYP2C9 [4]. Moreover, the structures of 2-ene VPA
(Fig. 1B) and 4-ene VPA (Fig. 1C) are similar to those of hypoglycin
and 4-pentenoic acid, known as hepatic toxicants [5–6]. VPA can
be used alone or in combination with other antiepileptic drugs to
treat epilepsy. Therefore, it is necessary to simultaneously monitor
VPA and its toxicant, ene-metabolites in epilepsy patients. How-
ever, a small molecule with simple chemical structure is a chal-
lenge for the determination with tandem mass spectrometry.
Especially, 2-ene VPA and its structural isomer 4-ene VPA both
have the same precursor/product transitions, which is an analy-
tical challenge to ensure their baseline separation.
Numerous techniques have been reported for the quantiﬁcation
of VPA in biological samples, mainly including ﬂuorescence po-
larization immunoassay [7], thin layer chromatography-derivati-
zation [8], homogeneous enzyme-linked immunoassay [9], gas
chromatography [10], high performance liquid chromatographyis is an open access article under the CC BY-NC-ND license
Fig. 1. Chemical structures of (A) VAP, (B) 2-ene VAP and (C) 4-ene VAP.
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mass spectrometry (LC–MS/MS) [17]. However, the major dis-
advantages of these techniques were the low sensitivity and the
long retention time. Gao et al. [18] used LC–MS/MS to simulta-
neously determinate VPA and 4-ene VPA. Because no stable ion
fragments were produced during VPA, 2-ene VPA and 4-ene VPA
ionization, the pseudo multiple reaction monitoring (pseudo-
MRM) mode was chose to develop LC–MS/MS analytical method.
However, Dziadosz et al. [19] adopted the components of the
mobile phase with MRM as a novel way to analysis VPA in human
serum with LC–MS/MS. In this study, we once tried to use the
same method to determinate VPA, 2-ene VPA and 4-ene VPA, but
this measure could not be applied to 2-ene VPA and 4-ene VPA.
Because the concentrations of 2-ene VPA and 4-ene VPA are low, it
is impossible to inspect signal when formic acid is added into
mobile phase. Meanwhile, the concentration of VPA in pseudo-
MRM mode is higher than that in MRM mode with aqueous 0.1%
formic acid. Finally, pseudo-MRM was selected for determination
of VPA, 2-ene VPA and 4-ene VPA. Wilimowska [20] quantiﬁed the
variabity of concentrations of VPA and its selected metabolites,
2-ene VPA and 4-ene VPA. However, no speciﬁc LC–MS/MS
method was reported for simultaneous determination of VPA and
its two ene-metabolites, 2-ene VPA and 4-ene VPA, in biological
specimens up to date.
In order to better explain pharmacodynamics and tox-
icokinetics of VPA, 2-ene VPA and 4-ene VPA in the body, we es-
tablished a sensitive and high-throughput LC–MS/MS method for
simultaneous determination of VPA, 2-ene VPA and 4-ene VPA
based on solid-phase extraction (SPE) followed by gradient elution
program in human plasma. Finally, the method was fully validated
and successfully applied to therapeutic drug monitoring.2. Materials and methods
2.1. Chemicals and reagents
VPA, 2-ene VPA, 4-ene VPA (purity 498.0%) and probenecid
(internal standard, IS, purity 499.0%) were purchased from the
National Institute for the Control of Pharmaceutical and Biological
Products (Beijing, China). Acetonitrile (HPLC grade) was obtained
from Fisher Scientiﬁc (Fair Lawn, USA). Formic acid (HPLC grade)
was purchased from Tedia (Fairﬁeld, OH, USA). Deionized water
was obtained from a Millipore Milli-Q gradient water puriﬁcation
system (Molsheim, Franceo). Epilepsy patient plasma samples and
heparinized blank (drug-free) human plasma samples were ob-
tained from Changchun Blood Donor Service (Changchun, China).
2.2. Instruments
The LC–MS/MS system consists of an Agilent 1100 Series HPLC
system (Agilent Technologies, Palo Alto, USA) and an Applied
Biosystems Sciex Qtrap 5500 mass spectrometer (AppliedBiosystems, Sciex, Ontario, Canada) equipped with an electrospray
ionization (ESI) source. Acquisition and integration of data were
achieved by Applied Biosystems Analyst Software, version 1.5.2.
2.3. LC–MS/MS condition
The separation of VPA, 2-ene VPA and 4-ene VPA was performed
at 40 °C on an Agilent Poroshell SB-C18 column (50 mm4.6 mm i.
d., 2.7 μm) protected by a SecurityGuard C18 guard column
(4 mm 3.0 mm i.d., Phenomenex Inc., USA) with a mobile phase
that constituted water (A) and acetonitrile (B) at a ﬂow rate of
0.9 mL/min. The initial mobile phase was composed of 10% B. After
4.0 min, the composition was changed to 60% B; these conditions
were maintained for 0.5 min, after which the column was quickly
equilibrated with the initial mobile phase.
MS parameters were optimized by infusing a standard solution
of analytes or IS into the mass spectrometer through a syringe
pump. The mass spectrometer with ESI source was operated in the
negative ion mode. Nebulizer, heater and curtain gas pressure
were set at 40, 40 and 30 psi, respectively; dwell time was opti-
mized at 200 ms; ionspray voltage was regulated at 4500 V;
heater gas temperature was maintained at 600 °C; declustering
potentials (DP) 60 V and collision energies (CE) 12 eV were
found to be the best for analytes and IS. Unit resolution was used
for both Q1 and Q3 mass detection. MRM scan mode was used to
monitor ion transitions at m/z 143.0-143.0 for VPA, m/z 140.9-
140.9 for 2-ene VPA and 4-ene VPA, and m/z 283.9-239.9 for IS.
Data were collected and processed by Applied Biosystems Analyst
Software.
2.4. Preparation of calibration standards and quality control (QC)
samples
The stock solutions of VPA, 2-ene VPA and 4-ene VPA
(1 mg/mL) were successively prepared in ultra-pure water, stored
in a refrigerator at 4 °C prior to use, and then mixed correspond-
ingly to get mixed stock solution. Mixed working solutions of VPA,
2-ene VPA and 4-ene VPA were prepared by diluting prepared
mixed stock solution to 20, 40, 60, 80, 100 and 125 mg/mL for VPA,
1.0, 2.0, 3.0, 4.0, 5.0 and 6.25 mg/mL for 2-ene VPA, and 0.02, 0.04,
0.06, 0.08, 0.10 and 0.125 mg/mL for 4-ene VPA with drug-free
human plasma. QC samples were prepared independently in the
same way with concentrations of 30, 80 and 125 mg/mL for VPA,
1.5, 4.0 and 6.25 mg/mL for 2-ene VPA and 0.03, 0.08 and
0.125 mg/mL for 4-ene VPA. A stock solution of probenecid of
1 mg/mL was also prepared in ultra-pure water and diluted with
drug-free human plasma subsequently to obtain an IS working
solution of 0.05 mg/mL.
2.5. Sample preparation
Frozen human plasma samples from subjects were allowed to
thaw in a water-bath at room temperature and vortex-mixed
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standards, QC samples or test samples) was mixed with 50 mL of IS
working solution (0.05 mg/mL), and then diluted with 500 mL of
0.2% formic acid. The mixture was vortexed for 1 min and then
loaded on Waters Oasis HLB 1 mL/10 mg cartridge which had been
conditioned with 1.0 mL of methanol and equilibrated with 1.0 mL
of 0.2% formic acid. Finally, the cartridges were washed with
1.0 mL water and eluted from the cartridge by 2.0 mL of a mixture
of acetonitrile and water (4:1, v/v); then 20 mL of the eluent was
injected into the LC–MS/MS system.
2.6. Method validation
The developed method was fully validated for selectivity, cross-
talk, carryover, linearity, accuracy, precision, matrix effects, re-
covery and stability according to the Food and Drug Administra-
tion (FDA) guidance [21]. Selectivity of the method was performed
using six different sources of blank plasma samples and ensuring
no interfering peaks could be observed at retention time of the
analytes and IS. Cross-talk was assessed among MS/MS channels
by separately injecting a high concentration solution of calibration
curve of VPA, 2-ene VPA, 4-ene VPA and IS and then monitoring
the responses in other MS/MS channels. Carryover was evaluated
by injecting an upper limit of quantitation (ULOQ) followed by a
blank sample. The calibration standards were obtained by
weighted (1/x2) least-square linear regression based on the peak
area ratios of analytes to IS versus the nominal analyte con-
centration. To ensure linearity, the coefﬁcient (r2) should be more
than 0.99; meanwhile, the deviations of the calculated con-
centrations should be less than 15% of the nominal concentration
and a 720% deviation at the lower limit of quantiﬁcation (LLOQ)
was accepted. The accuracy and intra- and inter-day precision
were evaluated on six replicates of QC samples at low, medium
and high concentrations on three consecutive days. The accuracy
was demanded to be less than 15%, and both intra- and inter-day
precisions were required to be below 15% except for the LLOQ, at
which 720% was permitted.
To evaluate matrix effects and recovery of analytes and IS, three
mixtures should be prepared. Matrix effects were evaluated by
comparing peak areas of the analytes and IS in post-extraction
spike, which was obtained by the SPE with blank plasma samples,
and then mixing the solvent standards with those solvent stan-
dard solutions. Extraction recovery was obtained by comparing
peak areas of QC samples with those of post-extraction spikes at
three different concentrations (low, medium and high).
Stability of the analytes was assessed by analyzing QC samples
placed on storage for 60 days at 20 °C, for 2 h at room tem-
perature (25 °C) as well as after three freeze/thaw cycles. Stability
of pre-extraction spike on storage in autosampler vials at room
temperature for 2 h was also evaluated.
2.7. Clinical application
The validated LC–MS/MS method was applied to determine the
concentration of VPA, 2-ene VPA and 4-ene VPA in epilepsy patient
plasma refereed to therapeutic drug monitoring. Experimental
procedures were compliant with the ethical regulations of Jilin
University.3. Results and discussion
3.1. Optimization of mass spectrometry, chromatography and sample
preparation
VPA and its ene-metabolites, 2-ene VPA and 4-ene VPA, containcarboxy side chain. The negative ion mode was adopted in the LC–
MS/MS method since it produced higher intensity signals than the
positive ion mode. In this study, the abundance of deprotonation
ion [M–H]- was the maximum in the Q1 MS spectra of the analytes
and IS, but the poor fragmentation leading to low sensitivity is a
challenge of bioanalysis. Pseudo-MRM is an effective way to
overcome this with the same Q1 and Q3 ions and low collision
energy. As a result, the response of baseline and noise of analytes
was very high (41.0e4 cps) for VPA, 2-ene VPA and 4-ene VPA,
which brought great difﬁculties for sensitivity and chromato-
graphic separation. Finally, ion transitions were observed at m/z
143.0-143.0 for VPA, m/z 140.9-140.9 for 2-ene VPA and 4-ene
VPA, and m/z 283.9-239.9 for IS.
Because 2-ene VPA and 4-ene VPA possess the same transitions,
rapid and complete chromatographic separation is the most im-
portant issue that must be addressed. Several available C18
columns including Zorbax SB-C18, Zorbax SB-Aq, Zorbax extend-C18
and Poroshell SB-C18 were tested. At last, Agilent Poroshell SB-C18
column (50 mm4.6 mm i.d., 2.7 μm) was selected due to the ap-
proved baseline separation of 2-ene VPA and 4-ene VPA. The com-
position of the mobile phase was optimized through several trials in
order to achieve high sensitivity and symmetric peak shapes in
analysis of biological samples. The best result was obtained with a
mobile phase consisting of acetonitrile and water. Using this mobile
phase with Agilent Poroshell SB-C18 column, VPA, 2-ene VPA and
4-ene VPA could be simultaneously determined with a short run
time of only 7 min with gradient elution.
For the sample preparation, we have tried protein precipitation
(PPT), liquid–liquid extraction (LLE) and SPE. Asymmetric peaks
with poor sensitivity and signiﬁcant matrix effects were produced
by PPT using acetonitrile, methanol and perchloric acid. LLE with
several different organic solvents (dichloromethane, diethyl ether,
hexane, ethyl acetate and isopropanol with different ratio mix-
tures) was tried. Due to the great polarity difference between VPA
and its alkene metabolites, the recovery was not stable and sus-
tainable for the three analytes. Finally, SPE was found to give re-
producible extraction efﬁciency of analytes and IS from acidiﬁed
samples with almost no interference, low matrix effects and high
sensitivity. But deprotonation of VPA, 2-ene VPA and 4-ene VPA
having carboxy functional group eliminates the interaction with
SPE column. In order to ensure the three analytes keeping mole-
cular state and increase their retention behavior in C18 solid phase
extraction column, SPE column was equilibrated with 1.0 mL of
0.2% formic acid and plasma samples were diluted with 500 mL of
0.2% formic acid.
3.2. Selection of IS
Probenecid was selected as IS due to the similarity of retention
time and extraction efﬁciency and its adequate ionization response
in the negative ion mode.
3.3. Method validation
3.3.1. Speciﬁcity
As shown in the chromatograms of drug-free plasma (Fig. 2A),
no signiﬁcant interfering peaks from the endogenous substances
can be observed at the retention times of the analytes and IS.
Fig. 2B shows the chromatograms of a calibration standard of the
analytes and IS with a concentration of LLOQ. Fig. 2C shows the
chromatograms of plasma samples from an epilepsy patient 12 h
after continuous oral administration of 0.5 g sodium valproate
with IS added. No interference from endogenous substances in
plasma at the retention times of the analytes and IS was observed,
suggesting the selectivity of the analytes for the developed
method was satisfactory.
Fig. 2. Representative chromatograms of VPA, 4-ene VPA and IS in human plasma. (A) blank plasma sample, (B) blank plasma sample spiked with VPA, 2-ene VPA, 4-ene VPA
at LLOQ and IS at 0.50 μg/mL, and (C) an epilepsy patient's plasma sample collected 12 h after the oral administration of 0.5 g sodium valproate.
Table 1
Intra- and inter-day accuracy and precision for determination of VPA, 2-ene VPA







Intra-day Inter-day Intra-day Inter-day
VPA 30 0.6 0.8 5.0 5.5
80 8.3 10.0 3.8 4.0
100 5.2 11.0 2.0 3.2
2-ene VPA 1.5 1.4 2.0 4.0 5.0
4.0 2.7 3.6 5.0 5.4
5.0 7.2 9.0 2.0 2.3
4-ene VPA 0.03 3.7 7.0 0.5 1.0
0.08 6.4 9.0 11.0 12.0
0.10 6.0 10.0 5.2 6.3
Table 2
Matrix effect and recovery for the determination of VPA, 2-ene VPA, 4-ene VPA and
IS in human plasma.
Analytes Concentration (μg/mL) Matrix effect (%) Recovery (%)
VPA 30 97.9 105.0
80 98.1 96.9
100 99.0 101.5
2-ene VPA 1.5 100.1 105.2
4.0 99.4 97.0
5.0 98.6 96.4
4-ene VPA 0.03 99.9 103.0
0.08 99.4 106.7
0.1 97.8 101.4
IS 0.5 98.4 98.1
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ULOQ solutions of VPA, 2-ene VPA, 4-ene VPA and IS were in-
jected successively, and no peaks were observed in other MS/MS
channels at the retention times of the analytes and IS. No peaks of
the analytes or IS from the blank sample subsequently injected
after a ULOQ sample were observed, indicating no carryover from
residues in rotary sampling/switching valves.
3.3.3. Linearity
The linearity of VPA was within a concentration range of 20–
125 μg/mL with a typical regression curve of y¼5.7210–5
xþ0.328 (r¼0.9981). The calibration curve of 2-ene VPA was linear
over the concentration range of 1.06.25 μg/mL with a typical re-
gression curve of y¼5.7210–5xþ0.328 (r¼0.9981). The calibra-
tion range of 4-ene VPA was 0.02–0.125 μg/mL with a typical re-
gression curve of y¼6.02 10–4xþ0.00762 (r¼0.9984). It was
sufﬁcient for therapeutic drug monitoring based on oral adminis-
tration while at LLOQ the accuracy and precision was less than 12%.
3.3.4. Precision and accuracy
The precision and accuracy data of the method are summarized
in Table 1 which shows that the intra- and inter-day accuracy was
r11.0% and r12.0%, respectively.
3.3.5. Matrix effect
The matrix effect of the analytes and IS was 97.8%–100.1%, in-
dicating that ion suppression or enhancement from the plasma
matrix was negligible under the current conditions. The matrix
effect is represented in Table 2.
3.3.6. Recovery
The recoveries of the analytes and IS were determined by
comparing the peak areas of QC samples with those of the post-
Table 3
Stability of VPA, 2-ene VPA and 4-ene VPA in human plasma under different storage conditions.
Analytes Concentration (μg/mL) Long-term Post-preparation Freeze–thaw Bench-top
RE (%) RSD (%) RE (%) RSD (%) RE (%) RSD (%) RE (%) RSD (%)
VPA 30 4.2 5.5 3.8 9.8 6.2 8.7 3.9 9.9
100 3.8 0.9 2.6 7.0 3.2 4.1 7.6 8.8
2-ene VPA 1.5 2.3 8.0 2.4 9.4 4.3 8.8 5.3 10.0
5.0 1.6 7.6 5.4 5.6 4.8 9.0 5.8 11.0
4-ene VPA 0.03 4.6 4.3 4.3 7.0 8.9 7.8 6.0 10.9
0.1 3.7 5.1 6.7 8.0 6.9 9.9 7.3 8.4
Fig. 3. Mean plasma trough concentrations of VPA (63.375.7 μg/mL), 2-ene-VPA
(5.370.4 μg/mL) and 4-ene-VPA (0.05070.0035 μg/mL) in epilepsy patients
(n¼60) after oral administration of Debakin at 0.5 g twice daily.
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coveries of the analytes and IS are shown in Table 2.
3.3.7. Stability
The stability of the analytes in human plasma was evaluated
with QC samples stored for 60 days at 20 °C and 2 h at room
temperature (25 °C) as well as after three freeze/thaw cycles. The
stability of the analytes and IS in the mobile phase stored in au-
tosampler vials at room temperature for 4 h was also evaluated.
The result shows that the stability of the analytes is excellent and
the data are summarized in Table 3.
3.4. Application to therapeutic drug monitoring
The full validated LC–MS/MS method was applied to determine
VPA, 2-ene VPA and 4-ene VPA concentration in epilepsy patient
plasma. The study was approved by the Ethical Committee of the First
Hospital of Jilin University. Venous blood samples (4 mL) were col-
lected into EDTA tubes at 8:00 a.m. before oral administration of De-
bakin (sodium valproate sustained release tablets, 0.5 g) from 60 epi-
lepsy patients (mean age was 30 years old and mean body weight was
60 kg) with continuous oral administration of Debakin twice daily for
three months. Blood samples were centrifuged at 3500 rpm for 5 min
at 4 °C after collection, and the plasma was then transferred into
2 polypropylene tubes and stored at 20 °C until analysis. The aver-
age trough concentration in plasma was determined as 63.375.7,
5.370.4, 0.0570.004 μg/mL, respectively (Fig. 3). The retention time
of VPA, 2-ene VPA, 4-ene VPA and IS was 4.46, 4.38, 4.08 and 4.66 min,
respectively.
4. Conclusions
A rapid and sensitive LC–MS/MS assay for the simultaneous
determination of VPA, 2-ene VPA and 4-ene VPA in epilepsypatient plasma after oral administration of a single dose of 0.5 g
Debakin has been developed and validated. The major advantages
of the method are low matrix effect, high recovery, small sample
volume (20 μL) and the relative short run time for high through-
put analysis for therapeutic drug monitoring. The developed LC–
MS/MS method can be successfully applied to routine therapeutic
monitoring for VPA, 2-ene VPA and 4-ene VPA in epilepsy patients.References
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